Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the phase 3 BE COMPLETE Study and its open-label extension up to 1 year

Objective

To assess the long-term efficacy and safety of bimekizumab (BKZ) treatment up to 52 weeks in patients with active psoriatic arthritis (PsA) and prior inadequate response or intolerance to tumour necrosis factor-a inhibitors (TNFi-IR).

Introduction

- BKZ is a humanised monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A.
- BKZ has shown superior efficacy to 16 weeks versus placebo (PBO) and tolerability in patients with active PsA in two phase 3 studies, BE OPTIMAL (naïve to biologic disease-modifying antirheumatic drugs [bDMARDs]) and BE COMPLETE (TNFi-IR).¹²
- The efficacy and tolerability of BKZ to 52 weeks has also been demonstrated in BE OPTIMAL.³
- Patients with PsA and TNFi-IR typically exhibit reduced treatment responses compared with biologic-naïve patients,^{4,5} so identifying treatments that effectively manage the long-term clinical needs of these patients is important.

Methods

- BE COMPLETE included a 16-week double-blinded, PBO-controlled period.²
- Patients were randomised 2:1 to subcutaneous BKZ 160 mg or PBO every 4 weeks (Q4W)
- Patients who completed Week 16 were eligible for entry into an open-label extension, BE VITAL Figure 1).⁶ Upon entry, PBO-randomised patients switched to receive BKZ (PBO/BKZ).
- BE VITAL included patients from BE OPTIMAL and BE COMPLETE; data here are only for patients randomised at baseline (Week 0) of BE COMPLETE, up to 1 year
- Efficacy data reported are observed case or have imputed missing data using non-responder imputation (binary) or multiple imputation (continuous).
- The number of treatment-emergent adverse events (TEAEs) to Week 52 are reported for patients who received ≥ 1 dose of BKZ, including patients who switched from PBO to BKZ at Week 16.


Results

- 388/400 (97.0%) patients completed Week 16; 377 (94.3%) entered BE VITAL and 347 (86.8%) completed Week 52.
- Baseline characteristics were comparable between groups (Table 1)
- Improvements in joint and skin responses with BKZ treatment at Week 16 were sustained to Week 52 (Figure 2 and Table 2).
- Patients who switched to BKZ at Week 16 demonstrated improvements in efficacy responses to Week 52 (Figure 2 and Table 2).
- To Week 52, 243/388 (62.6%) patients had >1 TEAE whilst receiving BKZ (exposure-adjusted incident rate [EAIR]: 126.0 per 100 patient-years; Table 3).
- The most frequent TEAEs were coronavirus infection, oral candidiasis, nasopharyngitis and urinary tract infection (Table 3).
- All Candida infections were mild or moderate and none were systemic.
- Two cases of oral candidiasis led to study discontinuation.
- There was one death, considered unrelated to study treatment by the investigator (BKZ-treated patient with a history of cardiac events).

Conclusions

In patients with PsA and prior TNFi-IR, BKZ treatment demonstrated sustained improvements across joints and skin from Week 16 to Week 52. Patients who switched to BKZ at Week 16 also displayed meaningful improvements in efficacy responses at Week 52. The safety profile was consistent with previous reports.¹⁻³

Figure 1 BE COMPLETE and BE VITAL study design



*BE VITAL includes patients from the BE OPTIMAL and BE COMPLETE studies; results are only presented for patients from BE COMPLETE. BKZ-treated patients were eligible to receive rescue therapy from Week 16 at the discretion of the investigator, while continuing to receive BKZ

Baseline characteristics Table 1

	PBO n=133	BKZ 160 mg Q4 n=267
Age, years, mean (SD)	51.3 (12.9)	50.1 (12.4)
Male , n (%)	60 (45.1)	130 (48.7)
BMI, kg/m ² , mean (SD)	29.0 (5.4) 30.1	
Time since first diagnosis of PsA, ^a years, mean (SD)	9.2 (8.1)	9.6 (9.9)
TJC (of 68 joints), mean (SD)	19.3 (14.2)	18.4 (13.5)
SJC (of 66 joints), mean (SD)	10.3 (8.2)	9.7 (7.5)
hs-CRP ≥6 mg/L , n (%)	59 (44.4)	118 (44.2)
Patients with psoriasis involving ≥3% BSA, n (%) / PASI score, ^b mean (SD)	88 (66.2) / 8.5 (6.6)	176 (65.9) / 10.1 (
HAQ-DI score, mean (SD)	1.04 (0.69) 0.97 (0	
SF-36 PCS score, mean (SD)	35.9 (10.2) 36.4 (
Dactylitis (LDI >0), ^{c.d} n (%) / LDI score, ^e mean (SD)	14 (10.5) / 66.4 (127.6)	34 (12.7) / 72.7 (11
Enthesitis (LEI >0), ^{d,f} n (%) / LEI score, ^g mean (SD)	36 (27.1) / 2.9 (1.6) 106 (39.7)	
Nail psoriasis (mNAPSI >0), ^d n (%) / mNAPSI score, ^h mean (SD)	83 (62.4) / 4.5 (2.8)	159 (59.6) / 4.3 (2

Randomised set a Data missing for 1 PBO patient: 1 BK7 patient: bPatients with psoriasis involving >3% BSA at baseline: The presence of dactylitis was defined by a score greater than 0 on the Leeds Dactylitis Index (higher scores indicate a greater number of affected sites); "Data missing for 1 PBC patient; "In patients with dactylitis at baseline; The presence of enthesitis was defined by a score greater than 0 on the Leeds Dactylitis Index (range 0 to 6, with higher scores)." ndicating a greater number of affected sites); ^aIn patients with enthesitis at baseline; ^hIn patients with nail psoriasis at baselir

ACR: American College of Rheumatology: ACR 20/50/70; http://www.acs.index: BSA: body surface area: CfB: change from baseline: ACR: adverse event: bDMARD: biologic disease-modifying antirheumatic drug: BKZ: bimekizumab: BMI: body surface area: CfB: change from baseline: EAIR: exposure-adjusted incident rate per 100 patient-vears: HAQ-DI: Health Assessment Questionnaire-Disability Index: hs-CRP: high-sensitivity C-reactive protein: IBD: inflammatory bowel disease-modifying antirheumatic drug: BKZ: bimekizumab: BMI: body surface area: CfB: change from baseline: EAIR: exposure-adjusted incident rate per 100 patient-vears: HAQ-DI: Health Assessment Questionnaire-Disability Index: hs-CRP: high-sensitivity C-reactive protein: IBD: inflammatory bowel disease-modifying antirheumatic drug: BKZ: bimekizumab: BMI: body surface area: CfB: change from baseline: EAIR: exposure-adjusted incident rate per 100 patient-vears: HAQ-DI: Health Assessment Questionnaire-Disability Index: hs-CRP: high-sensitivity C-reactive protein: IBD: inflammatory bowel disease-modifying antirheumatic drug: BKZ: bimekizumab: BMI: body surface area: CfB: change from baseline: EAIR: exposure-adjusted incident rate per 100 patient-vears: HAQ-DI: Health Assessment Questionnaire-Disability Index: hs-CRP: high-sensitivity C-reactive protein: IBD: inflammatory bowel disease-modifying antirheumatic drug: BKZ: bimekizumab: BKI: bimekizumab: IL: interleukin; LDI: Leeds Dactylitis Index; LEI: Leeds Enthesitis Index; MACE: major adverse cardiovascular event; MDA: minimal disease activity; MI: multiple imputation; mNAPSI: Psoriasis Area and Severity Index; PASI 75/90/100% improvement from baseline in Psoriasis Area and Severity Index; PASI: Psoriasis Area and Severity Index; PASI: Psoriasis Area and Severity Index; PASI 75/90/100% improvement from baseline in Psoriasis Area and Severity Index; PASI: Psoriasis Area and Severity Index; PASI: Psoriasis Area and Severity Index; PASI: Psoriasis Area and Severity Index; PASI 75/90/100% improvement from baseline in Psoriasis Area and Severity Index; PASI: Psoriasis Area and Severit years at risk; Q4W: every four weeks; SD: standard deviation; SE: standard error; SF-36 PCS: Short-Form 36-item Health Survey Physical Component Summary; SJC: swollen joint count; TNFi: tumour necrosis factor-a inhibitor; TNFi-IR: prior inadequate response or intolerance to tumour necrosis factor-a inhibitor; TNFi-IR: prior inadequate response or intolerance to tumour necrosis factor-a inhibitor; SD: standard deviation; SD: standard deviation; SE: standard deviation; SE: standard deviation; SIC: swollen joint count; TNFi-IR: prior inadequate response or intolerance to tumour necrosis factor-a inhibitor; SIC: swollen joint count; SIC:

Medical School, Rochester, New York, USA: 6The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Eukuoka, Japan: 7Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan: 8Div y, The Icahn School of Medicine at Mount Sinai, New York, New York, USA; ¹²Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK; ¹³UCB Pharma. Slough. UK: ¹⁵UCB Pharma. Norrisville. North Carolina. USA: ¹⁶Department of Dermatology. Harvard Medica ment of Medicine, Brigham and Women's Hospital, Boston, Massa

References: ¹McInnes IB et al. The Lancet 2023;401:25–37: ²Merola JF et al. Chin Exp Dermatol 2022;47:1627–35; BE VITAL: https://clinicaltrials.gov/study/NCT04009499?tab=results. Author Contributions to study conception/design, or acquisition/analys nterpretation of data: LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DDG, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DC, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DC, LG, ABG, RBW, BI, RB, JC, JFM; Final approval of the publication; LCC, RBML, IBM, PJM, CTR, YT, AA, FB, DC, LG, ABG, RBW, FINAL APPROVAL APP Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB Pharma; Consultant for AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Moorartis, Pfizer, and UCB Pharma; Consultant for AbbVie, AstraZeneca, BMS, Eli Lilly, Novartis, Pfizer, and UCB Pharma; Research grants from AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Novartis, Pfizer, and UCB Pharma; Owner of Rheumatology Consultancy BV, an AMS company under Dutch law. **IBM**: Consulting fees and honoraria from AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Evelo, Janssen, Lilly, Moonlake, Novartis, Pfizer, and UCB Pharma; Research grants from AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Evelo, Janssen, Lilly, Moonlake, Novartis, and UCB Pharma; Research grants from AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Janssen, Novartis, Pfizer, and UCB Pharma; Research grants from AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Janssen, Novartis, Pfizer, Sun Pharma; Consultancy fees from AbbVie, Acelyrin, Aclaris, Amgen, BMS, Boehringer Ingelheim, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma; Consultancy fees from AbbVie, Amgen, BMS, Boehringer Ingelheim, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB Pharma; Consultancy fees from AbbVie, Amgen, BMS, Boehringer Ingelheim, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, Novartis, Pfizer, Sun Pharma; Consultancy fees from AbbVie, Amgen, BMS, Boehringer Ingelheim, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma; Consultancy fees from AbbVie, Amgen, BMS, Boehringer Ingelheim, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma; Speakers' bureau for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, Sovartis, Pfizer, Sun Pharma; Speakers' bureau for AbbVie, Amgen, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma; Speakers' bureau for AbbVie, Amgen, E Amgen, Eli Lilly, Glicad, Janssen, Novartis, Prizer, Jan Pharma, and Ocb Pharm UCB Pharma. LG: Grants from AbbVie, Biogen, Lilly, Novartis, Sandoz, UCB Pharma; Personal fees from AbbVie, Amgen, BMS, Celltrion, Galapagos, Janssen, Lilly, MSD, Novartis, Sandoz, UCB Pharma; Personal fees from AbbVie, Received research, and visory board member and vis education grants from AnaptypsBio, BMS, Moonlaker, Finanda VCB, Pharma, (all particip), Biogen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, GSK, Janssen, LEO Pharma, Rearch grants to this institution from AbVie, Alminia, Van. Acenta, Astellas, Avillion, Biogen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, GSK, Janssen, LEO Pharma, Rearch grants to this institution from AbVie, Alminia, Ital and the patients, and UCB Pharma, Rearch grants to this institution from AbVie, Alminia, Ital and the patients, and UCB Pharma, Rearch grants to this institution from AbVie, Alminia, Ital and the patients, and UCB Pharma, Rearch grants to this institution from AbVie, Alminia, Ital and Ita e Costello Medical Creative team for design support. This study was funded by UCB Pharma. All costs associated with development of this presentation were funded by UCB Pharma. Previously presented at EULAR 2023.

Presented at the 32nd European Academy of Dermatology and Venereology Congress | Berlin, Germany | 11–14 October 2023

Laura C. Coates,¹ Robert B.M. Landewé,² lain B. McInnes,³ Philip J. Mease,⁴ Christopher T. Ritchlin,⁵ Yoshiya Tanaka,⁶ Akihiko Asahina,⁷ Frank Behrens,⁸ Dafna D. Gladman,⁹ Laure Gossec,¹⁰ Alice B. Gottlieb,¹¹ Richard B. Warren,^{12,13} Barbara Ink,¹⁴ Rajan Bajracharya,¹⁴ Jason Coarse,¹⁵ Joseph F. Merola^{16,17}




Table 2 Additional efficacy endpoints at Week 16 and Week 52 (NRI)

NRI, n/N (%), unless otherwise specified	PBO BKZ 160 mg Q4W (Weeks 0–16) → (Weeks 16–52) n=133 n=133		BKZ 160 mg Q4W n=267	
	Week 16	Week 52	Week 16	Week 52
PASI 75 response ^a	9/88 (10.2)	71/88 (80.7)	145/176 (82.4)	148/176 (84.1)
Enthesitis resolution ^b	8/36 (22.2)	21/36 (58.3)	52/106 (49.1)	60/106 (56.6)
Dactylitis resolution ^c	6/14 (42.9)	12/14 (85.7)	24/34 (70.6)	29/34 (85.3)
Nail psoriasis resolution ^d	12/83 (14.5)	51/83 (61.4)	73/159 (45.9)	107/159 (67.3)
HAQ-DI CfB, MI, mean (SE)	-0.07 (0.04)	-0.35 (0.05)	-0.38 (0.03)	-0.39 (0.03)
	Week 16	Week 40*	Week 16	Week 40*
SF-36 PCS CfB, MI, mean (SE)	1.4 (0.7)	7.3 (0.9)	7.3 (0.5)	8.4 (0.6)

andomised set. Previously reported data through Week 16 included for reference.2 *Data not collected at Week 52 for SF-36 PCS. In patients with psoriasi wolving >3% BSA at baseline: Patients with enthesitis at baseline (LEI >0): Patients with dactylitis at baseline (LDI >0): Patients with nail osoriasis at baseline

Safety to Week 16 and Week 52 Table 3

	Weeks 0–16ª (Double-blinded period)		Weeks 16–52 (Open-label period)	Weeks 0–52 (Overall study period)	
n (%) [EAIR]	PBO n=132 (PYAR: 42.5)	BKZ 160 mg Q4W n=267 (PYAR: 87.1)	PBO/BKZ 160 mg Q4W [♭] n=121 (PYAR: 80.3)	BKZ 160 mg Q4W n=267 (PYAR: 259.5)	BKZ 160 mg Q4W Total ^b n=388 (PYAR: 339.8)
Any TEAE	44 (33.3)	108 (40.4)	68 (56.2) [127.7]	175 (65.5) [125.4]	243 (62.6) [126.0]
Severe TEAEs	0.0	5 (1.9)	3 (2.5)°	14 (5.2) ^c	17 (4.4) ^c
Study discontinuation due to TEAEs	0.0	2 (0.7)	6 (5.0) [7.6]	10 (3.7) [3.9]	16 (4.1) [4.8]
Drug-related TEAEs	4 (3.0)	35 (13.1)	21 (17.4)°	66 (24.7)°	87 (22.4) ^c
Serious TEAEs	0.0	5 (1.9)	8 (6.6) [10.2]	15 (5.6) [6.0]	23 (5.9) [7.0]
Deaths	0.0	0.0	1 (0.8) ^{c,d}	0.0	1 (0.3) ^{c,d}
Most frequent TEAEs ^e					
Coronavirus infection	6 (4.5)	5 (1.9)	7 (5.8) [8.9]	21 (7.9) [8.4]	28 (7.2) [8.5]
Oral candidiasis	0.0	7 (2.6)	7 (5.8) [9.0]	17 (6.4) [6.8]	24 (6.2) [7.3]
Nasopharyngitis	1 (0.8)	10 (3.7)	4 (3.3) [5.0]	19 (7.1) [7.7]	23 (5.9) [7.0]
Urinary tract infection	3 (2.3)	5 (1.9)	4 (3.3) [5.1]	19 (7.1) [7.7]	23 (5.9) [7.0]
Serious infections	0.0	2 (0.7)	3 (2.5) [3.8]	4 (1.5) [1.6]	7 (1.8) [2.1]
Opportunistic infections	0.0	0.0	1 (0.8) [1.3] ^f	0.0	1 (0.3) [0.3] ^f
Neutropenia	0.0	4 (1.5) ^g	0.0	5 (1.9) [2.0] ^h	5 (1.3) [1.5] ^h
Hypersensitivity	1 (0.8)	7 (2.6)	4 (3.3) [5.1]	15 (5.6) [6.0]	19 (4.9) [5.8]
Injection site reactions	0.0	3 (1.1)	0.0	6 (2.2) [2.4]	6 (1.5) [1.8]
Adjudicated MACE	0.0	0.0	2 (1.7) [2.5] ⁱ	0.0	2 (0.5) [0.6] ⁱ
Malignancies excluding non-melanoma skin cancer	0.0	0.0	1 (0.8) [1.3] ^j	2 (0.7) [0.8] ^k	3 (0.8) [0.9] ^{j,k}
Non-melanoma skin cancer	1 (0.8) ¹	0.0	0.0	0.0	0.0

Safety set. No cases of active tuberculosis, definite or probable adjudicated IBD or uveitis were reported. ªEAIRs not available for double-blinded includes patients who switched from PBO to BKZ and only includes TEAEs occurring whilst receiving BKZ; "EAIRs not available; "Sudden death in 54-year old patient with a history of hypertension, aortic regurgitation, electrocardiogram changes of coronary artery disease; no further information available; no autops vas performed; *Most frequent adverse events are those occurring in ≥5% of patients in any study arm; '1 oesophageal candidiasis; *3 neutropenia; 1 neutroph ount decreased; 14 neutropenia; 1 neutrophil count decreased; 1 sudden death; 1 cerebral haemorrhage; 1 prostate cancer; 14 endometrial cancer stage l gastric cancer recurrent: ¹1 basal cell carcinoma

Previously Presented at EULAR 2023 | Milan, Italy | 31 May-3 June 2023

PO704



scan the QR code or visit Poster ID: PO704 Link expiration: 28 October 202